Literature DB >> 12921752

IL-4 and many roads to lupuslike autoimmunity.

Ram Raj Singh.   

Abstract

Interleukin-4 (IL-4) is a multifunctional cytokine. Although most studies have focused on the B-cell stimulatory and Th2 promoting properties of IL-4 in the development of autoantibodies and autoantibody-mediated diseases, a few reports suggest a T-cell suppressor role for this cytokine in lupus. Since these properties of IL-4 may sometimes result in opposing outcomes, amplifying or inhibitory, on overall B-cell functions, it is not surprising that a few studies have found no role for IL-4 in the development of autoantibodies and lupus. Evidence for a more novel role for IL-4 in the development of lupus nephritis comes from recent studies, which suggests that IL-4 may directly promote extracellular matrix deposition in the glomeruli. Consistent with this idea, blockade of IL-4 by antibody treatment or of its signaling by inactivation of the Stat6 gene ameliorates glomerulosclerosis and delays or even prevents the development of end-stage renal disease, despite the presence of high levels of IgG anti-dsDNA Antibodies. Thus, IL-4 may serve multiple roles in the development of lupus: it may enhance autoantibody production via its direct B-cell effects, protect against autoimmunity via its T-cell suppressor effect, or perpetuate tissue damage via its direct effects on target organs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12921752     DOI: 10.1016/s1521-6616(03)00145-1

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  19 in total

1.  B cells require "nurturing" by CD4 T cells during development in order to respond in chronic graft-versus-host model of systemic lupus erythematosus.

Authors:  Arpita Choudhury; Philip L Cohen; Robert A Eisenberg
Journal:  Clin Immunol       Date:  2010-04-08       Impact factor: 3.969

Review 2.  Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation.

Authors:  A Jäger; V K Kuchroo
Journal:  Scand J Immunol       Date:  2010-09       Impact factor: 3.487

3.  IL-4-STAT6 signal transduction-dependent induction of the clinical phase of Sjögren's syndrome-like disease of the nonobese diabetic mouse.

Authors:  Cuong Q Nguyen; Jue-hua Gao; Hyuna Kim; Daniel R Saban; Janet G Cornelius; Ammon B Peck
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

4.  An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis.

Authors:  Deijanira Alves De Albuquerque; Vijay Saxena; David E Adams; Gregory P Boivin; Hermine I Brunner; David P Witte; Ram Raj Singh
Journal:  Kidney Int       Date:  2004-03       Impact factor: 10.612

5.  Time course of cytokine upregulation in the lacrimal gland and presence of autoantibodies in a predisposed mouse model of Sjögren's Syndrome: the influence of sex hormones and genetic background.

Authors:  Stefanie Czerwinski; Safinaz Mostafa; Vanessa Seamon Rowan; Ana Maria Azzarolo
Journal:  Exp Eye Res       Date:  2014-09-11       Impact factor: 3.467

6.  Estradiol targets T cell signaling pathways in human systemic lupus.

Authors:  Emily Walters; Virginia Rider; Nabih I Abdou; Cindy Greenwell; Stan Svojanovsky; Peter Smith; Bruce F Kimler
Journal:  Clin Immunol       Date:  2009-09-30       Impact factor: 3.969

Review 7.  Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models.

Authors:  Simanta Pathak; Chandra Mohan
Journal:  Arthritis Res Ther       Date:  2011-09-30       Impact factor: 5.156

Review 8.  Lupus nephritis: current update.

Authors:  Ramesh Saxena; Tina Mahajan; Chandra Mohan
Journal:  Arthritis Res Ther       Date:  2011-09-28       Impact factor: 5.156

9.  Multiple signaling pathways are involved in the interleukine-4 regulated expression of DC-SIGN in THP-1 cell line.

Authors:  Changzhong Jin; Lijuan Wu; Jie Li; Meixin Fang; Linfang Cheng; Nanping Wu
Journal:  J Biomed Biotechnol       Date:  2012-05-17

10.  pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis.

Authors:  Suzanne Kafaja; Isela Valera; Anagha A Divekar; Rajan Saggar; Fereidoun Abtin; Daniel E Furst; Dinesh Khanna; Ram Raj Singh
Journal:  JCI Insight       Date:  2018-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.